Molecular Mechanisms of Combination Adjuvants (MMCA)(U01)
The summary for the Molecular Mechanisms of Combination Adjuvants (MMCA)(U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Molecular Mechanisms of Combination Adjuvants (MMCA)(U01): This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are used in these studies must already have shown immune boosting activity when used individually in licensed or unlicensed vaccines (e.g. experimental or candidate vaccines).
The purpose of this FOA is to build upon the investment the NIAID has already made into adjuvant research, by combining previously identified and characterized adjuvants and characterizing their immune stimulating activity. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAIDs overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations which will improve the immunogenicity of vaccines while addressing concerns related to reactogenicity.
The purpose of this FOA is to build upon the investment the NIAID has already made into adjuvant research, by combining previously identified and characterized adjuvants and characterizing their immune stimulating activity. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAIDs overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations which will improve the immunogenicity of vaccines while addressing concerns related to reactogenicity.
Federal Grant Title: | Molecular Mechanisms of Combination Adjuvants (MMCA)(U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-AI-15-005 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.855, 93.856 |
CFDA Descriptions: | Allergy, Immunology and Transplantation Research; Microbiology and Infectious Diseases Research |
Current Application Deadline: | Jul 9, 2015 |
Original Application Deadline: | Jul 9, 2015 |
Posted Date: | Feb 10, 2015 |
Creation Date: | Feb 10, 2015 |
Archive Date: | Aug 9, 2015 |
Total Program Funding: | $4,000,000 |
Maximum Federal Grant Award: | $350,000 |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- For profit organizations other than small businesses
Special district governments
Public housing authorities/Indian housing authorities
Independent school districts
County governments
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal governments (Federally recognized) - Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. - Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-005.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Tailoring HIV Curative Strategies to the Participant (UM1 Clinical Trial Not Allowed)
- • Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scal...
- • NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
- • NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Tria...
- • Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical T...
- • Center for HIV/AIDS Vaccine Immunology (CHAVI)
- • Genomics of Transplantation Cooperative Research Program
- • Asthma and Allergic Diseases Cooperative Research Centers
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)